Phathom Pharmaceuticals (PHAT) Non-Current Debt (2019 - 2026)

Phathom Pharmaceuticals (PHAT) has 8 years of Non-Current Debt data on file, last reported at $163.7 million in Q1 2026.

• Non-Current Debt for Q1 2026 came in at $163.7 million, down 19.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $163.7 million (down 19.47% YoY), and the FY2025 annual result was $209.1 million, up 3.81% from the prior year.
• Non-Current Debt fell to $163.7 million in Q1 2026 per PHAT's latest filing, from $209.1 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $209.1 million in Q4 2025 and troughed at $91.0 million in Q1 2022.
• A 5-year average of $146.6 million and a median of $149.0 million in 2024 frame the typical range for Non-Current Debt.
• The sharpest annual moves came in 2022 and 2026: Non-Current Debt jumped 155.82% in 2022, then dropped 19.47% in 2026.
• A 5-year view of Non-Current Debt shows it stood at $95.3 million in 2022, then soared by 44.69% to $137.8 million in 2023, then surged by 46.12% to $201.4 million in 2024, then increased by 3.81% to $209.1 million in 2025, then declined by 21.72% to $163.7 million in 2026.
• Business Quant data shows PHAT's Non-Current Debt at $163.7 million in Q1 2026, $209.1 million in Q4 2025, and $207.1 million in Q3 2025.